2005
DOI: 10.1016/j.pupt.2004.12.010
|View full text |Cite
|
Sign up to set email alerts
|

Effect of 5-hydroxytryptamine on vagal C-fiber subtypes in guinea pig lungs

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

5
36
0

Year Published

2005
2005
2024
2024

Publication Types

Select...
6
3
1

Relationship

2
8

Authors

Journals

citations
Cited by 54 publications
(41 citation statements)
references
References 21 publications
5
36
0
Order By: Relevance
“…The activation profile of C-fibers depends on the fiber subtype. For example, in guinea pigs, jugular and nodose C-fibers respond to capsaicin and bradykinin, but only nodose C-fibers respond to serotonin (15), ATP (13), and adenosine (unpublished observations). Differences in chemical activation have also been noted between bronchial and pulmonary C-fibers in dogs and cats (16).…”
Section: Nociceptorsmentioning
confidence: 92%
“…The activation profile of C-fibers depends on the fiber subtype. For example, in guinea pigs, jugular and nodose C-fibers respond to capsaicin and bradykinin, but only nodose C-fibers respond to serotonin (15), ATP (13), and adenosine (unpublished observations). Differences in chemical activation have also been noted between bronchial and pulmonary C-fibers in dogs and cats (16).…”
Section: Nociceptorsmentioning
confidence: 92%
“…The nodose and jugular C-fiber neurons could be readily distinguished pharmacologically. Both subtypes responded directly to capsaicin and bradykinin, but only the nodose C-fibers responded with action potential discharge to ATP and other purinergic P2X receptor-selective agonists, adenosine receptor (A1 and A2A) agonists, and 5-HT3 receptor agonists (5,6,35). In addition, the jugular C-fibers were more apt to express neuropeptides than the nodose C-fibers (35).…”
mentioning
confidence: 99%
“…For example, our previous studies indicate that nodose but not jugular C-fibers are activated by adenosine A1 or A2 receptor agonists, 5-HT3 receptor agonists, and ATP/purinergic P2X2/3 receptor agonists (10,11,26). As an alternative approach we have used short hairpin RNA (shRNA) technology to modify gene expression in subsets of vagal sensory ganglia neurons (14).…”
mentioning
confidence: 99%